Moonbird B.V.

Moonbird B. V. , based in Belgium, specializes in innovative handheld breathing devices that enhance relaxation and sleep quality through guided breathing techniques. Founded in Brussels, Belgium, Moonbird B.

V. develops handheld devices aimed at improving users' breathing patterns to foster relaxation and better sleep. The company experienced no major pivots or strategic changes since its inception. The latest funding round occurred in June 2025, when Moonbird attracted a new investor, ScaleFund, raising an undisclosed amount.

Moonbird has successfully completed 1 deal. Moonbird specializes in handheld breathing devices designed to promote relaxation and improve sleep quality through guided breathing techniques. The flagship product, known simply as moonbird, operates by expanding and contracting to help users synchronize their breathing patterns. This intuitive device can be used independently or paired with a mobile application that provides real-time biofeedback, such as heart rate and heart rate variability metrics.

The company also offers a child-friendly variant called moonbuddy, which mimics a natural breathing rhythm to assist children in calming down and regulating their emotions. Moonbird's products cater to both adults and children, targeting various end-use cases, including stress relief, sleep improvement, and emotional regulation. The primary markets for these products include the United States and multiple countries across Europe, where they are aimed at consumers seeking wellness solutions supported by emerging scientific research. Moonbird generates revenue through direct-to-consumer sales of its breathing devices, with distinct pricing structures for its flagship products.

The moonbird is offered at a price point of USD 99. 99, while the moonbuddy is priced at USD 99. 99 as well, catering to families looking for accessible wellness tools for their children. Additionally, the company markets a charging stand for USD 29.

99 to enhance user experience with the devices. Transactions occur primarily through online purchases, with the option for customers to engage in a 30-day trial period, allowing them to return the product for a full refund if they do not notice the benefits. This risk-free trial encourages customer confidence and promotes product trials, potentially leading to increased sales. Moonbird's revenue strategy also includes partnerships with insurance providers, facilitating reimbursement options that enhance product accessibility for users.

To support its growth, Moonbird B. V. plans to introduce new products designed for enhanced user experience and market penetration. The company aims to expand into additional European markets and the United States by 2025.

The funding raised in June 2025 will be strategically used to facilitate these product developments and market expansions.